General Anesthesia Clinical Trial
— PropofolTEOfficial title:
Therapeutic Equivalence Study of Propofol Using Target-Controlled Infusion of Propofol 2% (20 mg/mL) MCT Fresenius Compared With Diprivan® 20 mg/mL (AstraZeneca) in Patients Undergoing Elective Surgery
The purpose of this study is to evaluate the therapeutic equivalence, based on pharmacodynamic parameters of Propofol 2% (20 mg/mL) MCT Fresenius and Diprivan® 20 mg/mL (AstraZeneca), administered by target controlled infusion (TCI).
Status | Completed |
Enrollment | 71 |
Est. completion date | |
Est. primary completion date | February 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 64 Years |
Eligibility |
Inclusion Criteria: 1. Male or female subjects =18 years and <65 years old 2. Able to understand and give signed and dated written informed consent 3. Body mass index (BMI) =20 and =30 kg/m² at screening 4. ASA (American Society of Anesthesiologists) physical status 1 or 2 5. Undergoing elective, minor orthopedic, vascular, urological, or gynecological surgery 6. Patients should be affiliated to a social security scheme and benefit from the corresponding rights and cover Exclusion Criteria: 1. The following planned procedures are to be excluded: - Day surgery - Emergency surgery - Total hip or total knee replacement - Requiring opening of the great cavities of the body (cranium, thorax, peritoneum, or pelvis) - With routine risk, even if low, of hemorrhage severe enough to require administration of colloid or blood products - With routine risk, even if low, of death during or soon after the procedure - Vascular surgery involving the aorta, venae cavae, iliac arteries, or femoral arteries 2. Intended administration of IV medications through a central venous catheter (Note: a central venous catheter may be used to obtain Pharmacokinetic (PK) samples, though only if no port of the catheter is being used for administration of any other product, including crystalloid infusion at more than a "keep line open" rate) 3. Administration of general anesthesia or propofol within the 7 days prior to randomization 4. History of hypersensitivity to propofol, eggs, soya, peanuts, or any other constituent of the study drugs 5. ASA physical status =3 6. History of major anesthesia complications including, but not limited to: - Clinically significant hypoxia - Profound hypotension - Anaphylaxis or anaphylactic reactions - Unpredictable anesthesia agent requirements 7. History of difficult airway management including, but not limited to: - Problematic artificial ventilation with face mask - Repeated difficulty of placement of laryngeal mask airway (LMA) - Difficult laryngeal intubation (Cormack-Lehane grade 3 to 4) and requiring alternative technique e.g. fibre-optic or awake laryngeal intubation 8. History of difficult venous access 9. Myocardial infarction within 6 months of randomization or a cardiac reperfusion procedure within 6 weeks of randomization 10. Significant respiratory, cardiovascular, liver or renal disease as assessed by investigator 11. Active systemic infection (localized infection related to surgical procedure is allowable as long as there is no indication of systemic involvement) 12. History of psychiatric disorder, including use of sedatives or antidepressants for any reason, within 6 months prior to randomization 13. Alcohol or other substance abuse within 2 years prior to randomization, as well as for the duration of the study 14. Use of medication that could reduce the subject's respiratory and/or cardiac output 15. Female subjects who are pregnant, breastfeeding, or lactating 16. Hemoglobin <7.5 g/dL at screening or randomization 17. Platelets <50,000 x 10³/µL at screening or randomization 18. ECG findings detected at screening not consistent with the subject's medical history or warranting cardiology review 19. Participation in an interventional clinical study within 6 months of screening 20. History of Propofol infusion syndrome |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | CHU de Bordeaux, Groupe Hospitalier Pellegrin | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
Fresenius Kabi | Quintiles, Inc. |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to Loss of Eyelash Reflex (LOER) | The overall timeframe until LOER is observed depends on the patient and varies from only a few seconds up to 240 seconds in total. | Every ten seconds from the initiation of TCI anesthesia device until LOER occurs up to 150 seconds. If LOER has not occurred within this timeframe, target propofol concentration to be increased by 1 µg/mL every 60 seconds until LOER is observed. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04577430 -
Effects of Dexmedetomidine on Cardiac Electrophysiology in Patients Under General Anesthesia During Perioperative Period
|
N/A | |
Completed |
NCT03708692 -
Menstrual Cycle Phases on Recovery and Cognitive Function
|
||
Recruiting |
NCT03422315 -
Population Pharmacokinetics and Clinical Individual Dosage Regimen of Propofoll Injection
|
N/A | |
Completed |
NCT02771067 -
The Utility of Pulse Pressure Variation to Predict the Fluid Responsiveness During Pneumoperitoneum and Reverse-Trendelenburg Position
|
N/A | |
Completed |
NCT05063461 -
Evaluation of the Analgesia Nociception Index With Varying Remifentanil Concentrations Under Sevoflurane
|
N/A | |
Completed |
NCT03294226 -
Comparison of AuraGain With I-gel for Pediatric Patients
|
N/A | |
Not yet recruiting |
NCT03643029 -
The Accuracy of the Performance and Placement Test for Predicting Supraglottic Airway Device (SAD) Position in the Hypopharynx as Confirmed With Video Laryngoscopy
|
N/A | |
Completed |
NCT01945411 -
Assessment of Facial Measurements, the Length of Mouth Corner-mandible Angle and Incisors-mandible Angle, for Determining the Proper Sizes of Oropharyngeal Airway
|
N/A | |
Completed |
NCT01705743 -
Minimum Alveolar Concentration of Sevoflurane With Nitrous Oxide Inducing Isoelectric EEG
|
Phase 4 | |
Not yet recruiting |
NCT01678066 -
A Prospective Study to Bilaterally Compare a Non-Invasive Cardiac Output Monitor
|
N/A | |
Completed |
NCT00972491 -
The Optimal Time to Put Laryngeal Mask Airway in the Mouth Under General Anesthesia
|
N/A | |
Completed |
NCT00741507 -
Unhealthy Alcohol Drinking and Anesthetic Requirement in Women
|
N/A | |
Completed |
NCT01096212 -
Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia
|
Phase 4 | |
Completed |
NCT00599066 -
Intraoperative M-Entropy Measurements
|
N/A | |
Completed |
NCT00532402 -
Continuous and Discontinuous Determination of Propofol Concentration in Breathing Gas
|
N/A | |
Completed |
NCT00468494 -
Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia?
|
N/A | |
Recruiting |
NCT00492453 -
Spinal Versus General Anesthesia for Laparoscopic Cholecystectomy
|
N/A | |
Recruiting |
NCT03745079 -
Correlation Between Core Temperature and Skin Temperature Measured by 3M SpotOn
|
||
Completed |
NCT04094376 -
Comparison of Morning Operation and Evening Operation on Postoperative Sleep Quality and Pain Under General Anesthesia
|
N/A | |
Enrolling by invitation |
NCT03672734 -
Volume and pH of Gastric Contents in Patients Undergoing Gynecologic Laparoscopic Surgery During Emergence From General Anesthesia
|